As EGFR activation induces downstream signaling pathways driving tumor proliferation and/or anti-apoptosis, targeting activated EGFR signaling by using TKIs such as gefitinib or erlotinib markedly suppresses tumor growth, leading to remarkable clinical benefit for lung cancer patients. The gene discussed is EGFR; the disease is lung carcinoma.